
Decision to Grant Third EndoDrill® Patent in Japan

Cancer diagnostics company BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill® – the world's first market-cleared powered biopsy instrument for endoscopy – today announces that the Company has received a Decision to Grant from the Japan Patent Office (JPO). This means that the JPO has decided to approve BiBB's third patent application in Japan for EndoDrill®. A few formal steps remain before the patent is finally granted, after which it will be valid until 2041. Once the process is finalized, this will become the third granted patent in Japan for the EndoDrill® technology.

BiBB has received a decision from the JPO to grant patent JP 2022-560348, part of the Company's third patent family. The patent provides the EndoDrill® product series with protection for the instrument and its drive system in the Japanese market. The Company has three international patent applications for EndoDrill® that have entered national/regional phases, with patents granted to date in the USA (Notice of Allowance), Europe, Japan, India, and China. Remaining applications are being pursued toward approval to secure global protection for the market's first motorized endoscopic biopsy instrument.

"The decision by the Japan Patent Office to grant our third Japanese patent is strategically important and strengthens our global IP portfolio. It improves our prospects for a successful future global launch in partnership with distribution partners", says Fredrik Lindblad, CEO of BiBB.

This is a translation of the Swedish press release. If there should be any discrepancies, the Swedish language version prevails.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO
E-mail: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

This disclosure contains information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 24, 2025.

About BiBB

BiBBInstruments AB ("BiBB") develops and manufactures EndoDrill® – the world's first market-cleared, powered biopsy instrument for endoscopy. EndoDrill® enables rapid and high-quality core needle biopsies (CNB) for the diagnosis of serious cancers, including gastric, pancreatic, liver, lung, and bladder cancer. The product portfolio targets the fast-growing global market for endoscopic ultrasound-guided biopsy instruments (EUS/EBUS). EndoDrill® GI is FDA-cleared and CE-marked, with U.S. launch starting in 2025 in collaboration with TaeWoong Medical USA. EndoDrill® EBUS and EndoDrill® URO were CE-marked in 2024 and are planned for gradual launch. BiBB was founded by Dr Charles Walther and is headquartered at Medicon Village in Lund, Sweden. The share (BiBB) is listed on Spotlight Stock Market.